Strategic Wealth Partners’s GSK GSK Stock Holding History

Strategic Wealth Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.86K	Buy	150 +20	+15%	+$1.06K	﹤0.01%	972
2026 Q1	$7.18K	Sell	130 -8	-6%	-$434	﹤0.01%	963
2025 Q4	$6.77K	Buy	138 +79	+134%	+$3.69K	﹤0.01%	993
2025 Q3	$2.55K	Sell	59 -4,000	-99%	-$156K	﹤0.01%	1143
2025 Q2	$156K	Buy	+4,059	New	+$155K	0.01%	345
2024 Q4	–	Sell	-8,569	Closed	-$350K	–	320
2024 Q3	$350K	Sell	8,569 -3,220	-27%	-$132K	0.03%	234
2024 Q2	$454K	Buy	+11,789	New	+$496K	0.05%	208
2019 Q2	–	Sell	-87	Closed	-$5K	–	766
2019 Q1	$5K	Buy	+87	New	+$4.35K	﹤0.01%	627
2018 Q2	–	Sell	-1,914	Closed	-$93K	–	781
2018 Q1	$93K	Buy	1,914 +1,847	+2,757%	+$86K	0.05%	201
2017 Q4	$4K	Buy	+67	New	+$3.1K	﹤0.01%	632

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Strategic Wealth Partners's GSK Position: Q2 2026 in Review

Strategic Wealth Partners increased its GSK (GSK) stake by 15% in Q2 2026, buying an estimated $1.06K and bringing the position to 150 shares worth $7.86K. The position accounts for ﹤0.01% of the portfolio, ranked #972.

Strategic Wealth Partners first reported a position in GSK in Q4 2017 and has held it in 10 quarters since. The position peaked at $454K in Q2 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Strategic Wealth Partners held 150 shares of GSK worth $7.86K as of Q2 2026.
Strategic Wealth Partners bought 20 GSK shares in Q2 2026, an estimated $1.06K.
GSK made up ﹤0.01% of Strategic Wealth Partners's portfolio in Q2 2026, its #972 holding.
Strategic Wealth Partners first reported a position in GSK in Q4 2017 and has held it in 10 quarters since.
Strategic Wealth Partners's GSK position peaked at $454K in Q2 2024.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Strategic Wealth Partners's 13F filing for Q2 2026, filed 12 Aug 2026.